Newron's Parkinson's Drug Xadago Has Narrower Indication Than Teva's Azilect
After overcoming regulatory hurdles, Newron may have tough time competing in US against market stalwart Azilect; eight Parkinson's drugs are in Phase III trials.
You may also be interested in...
Original new drugs and biologics recently approved by US FDA.
Newron’s new Parkinson’s disease therapy, Xadago, approved in the US after a regulatory delay, is expected to be the first of several new products to be introduced in this long-neglected therapeutic sector.
Despite the long and troubled history of the molecule, Kyowa Hakko Kirin has persisted with the development of istradefylline for Parkinson's disease, but a new Phase III failure might be the last straw for the A2a antagonist.